Clinical Registry of Patients Under Treatment With Atypical Antipsychotics
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Antipsychotic drugs are characterized by blocking dopaminergic D2 receptors. They have been
found to be effective and safe for the treatment of schizophrenia, bipolar disorders,
depressive episodes associated with bipolar disorder, or psychotic symptoms in the context of
Parkinson's disease. Atypical antipsychotics have lower blocking potency on D2 receptors, at
the time that interact with serotoninergic, adrenergic and histaminergic receptors, among
others. Quetiapine extended-release has the same clinical efficacy as the immediate-release
formulation, but reduces the amount of daily doses, possibly contributing to increased
treatment adherence.
The purpose of this registry is to explore adherence to treatment, the occurrence of adverse
drug reactions and the clinical outcomes in a sample of patients under treatment with
atypical antipsychotics in several Central American countries. For this study, clinical data
will be extracted from the medical records of 1000 patients with schizophrenia, depressive
disorders or Parkinson's Disease with hallucinations. Occurrence of adverse drug reactions,
namely weight gain, somnolence, extrapyramidal reactions and symptoms of orthostatic
hypotension; adherence to treatment; and changes in quality of life and clinical status will
be assessed during the first 8 weeks of treatment.